Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 19/20 | 0.46 |
| ▸ | MMP13 | P45452 | 12/20 | 0.46 |
| ▸ | MMP2 | P08253 | 2/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP14 | P50281 | 1/20 | 0.40 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6771930 | 0.90 | MMP13 (0.53) | ADAMTS4MMP13MMP2MMP3MMP14 | |
| SCHEMBL6740800 | 0.78 | MMP13 (0.55) | ADAMTS4MMP13MMP2MMP3MMP14 | |
| SCHEMBL6774380 | 0.76 | MMP13 (0.53) | ADAMTS4MMP13MMP2MMP3MMP14 | |
| SCHEMBL6774034 | 0.71 | MMP2 (0.50) | ADAMTS4MMP13MMP2MMP3 | |
| SCHEMBL7497082 | 0.70 | MMP13 (0.40) | ADAMTS4MMP13MMP2MMP3 | |
| SCHEMBL7495698 | 0.68 | MMP2 (0.49) | ADAMTS4MMP13MMP2MMP3 | |
| SCHEMBL6773372 | 0.68 | MMP2 (0.49) | ADAMTS4MMP13MMP2MMP3 | |
| SCHEMBL6737736 | 0.67 | MMP13 (0.54) | ADAMTS4MMP13MMP2MMP3 | |
| SCHEMBL7391332 | 0.67 | MMP13 (0.54) | ADAMTS4MMP13MMP2MMP3 | |
| SCHEMBL6733656 | 0.66 | ADAMTS4 (0.58) | ADAMTS4MMP13MMP2MMP3MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225074-A1 | Dihetero-substituted metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-12-04 | — | — | US | claimed |
| US-6566381-B1 | For therapy of arthritis, cancer, cardiovascular disorder, skin disorder, ocular disorder, inflammation and gum disease | THE PROCTER & GAMBLE COMPANY | 2003-05-20 | — | — | US | claimed |
| JP-2002538146-A | — | — | 2002-11-12 | — | — | JP | claimed |
| EP-1165530-A2 | DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2002-01-02 | — | — | EP | claimed |
| WO-2000051993-A2 | DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-08 | — | — | WO | claimed |
| US-6762198-B2 | SUCH AS 2-((4'-METHOXY-(1,1'-BIPHENYL)-4-YL)-SULFONYL)-AMINO-3-(2-PHENOXYMETHYL -(1,3)DIOXAN-2-YL)PROPIONIC ACID | THE PROCTER & GAMBLE COMPANY | 2004-07-13 | — | — | US | disclosed |
| US-20030225074-A1 | Dihetero-substituted metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-12-04 | — | — | US | disclosed |
| US-6566381-B1 | For therapy of arthritis, cancer, cardiovascular disorder, skin disorder, ocular disorder, inflammation and gum disease | THE PROCTER & GAMBLE COMPANY | 2003-05-20 | — | — | US | disclosed |
| EP-1165530-A2 | DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000051993-A2 | DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225074-A1 | Dihetero-substituted metalloprotease inhibitors | ADAM9, ADAM17, ADAM8 | ADAMTS4 32/4885MMP13 42/4885MMP2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.